Latest Content

Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD

March 27th 2025, 3:00pm

By Ryan Scott

Article

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.

Rina-S Generates Antitumor Activity in Heavily Pretreated Ovarian Cancer

March 27th 2025, 1:00pm

By Dr. Elizabeth K. Lee

Video

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study.

A VXM01 Vaccine Combination Generates Safe Responses in Glioblastoma

March 26th 2025, 9:00pm

By Ryan Scott

Article

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with recurrent glioblastoma.

A Patient Advocate Highlights Kidney Cancer Awareness and Specialized Care

March 26th 2025, 8:00pm

By Ryan Scott

Video

Sid Sadler discusses kidney cancer awareness, patient advocacy and the need for specialized care to improve access to treatments and clinical trials.

Communication is Key When Transitioning Multiple Myeloma Care

March 26th 2025, 7:00pm

By Alex Biese

Article

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit.

Surviving Scans While Surviving Breast Cancer

March 26th 2025, 5:00pm

By Felicia Mitchell

Article

Survivors facing new medical concerns may fear the unknown, but perseverance is possible as they navigate unexpected challenges in their new normal.

Progress Reported in Phase 1 Trial of CLD-101 for Recurrent Glioma

March 26th 2025, 4:00pm

By Spencer Feldman

Article

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral doses.

FDA Approves Cabometyx for Some Neuroendocrine Tumors

March 26th 2025, 1:44pm

By Alex Biese

Article

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Navigating a Colorectal Cancer Diagnosis at a Young Age

March 26th 2025, 1:00pm

By Ryan Scott

Article

Melissa Ursini discussed her experience with a colorectal cancer diagnosis at age 37, highlighting her insights during Colorectal Cancer Awareness Month.

EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS

March 25th 2025, 9:00pm

By Ryan Scott

Article

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.

Top 3 Takeaways From ASCO GU 2025

March 25th 2025, 8:16pm

By Dr. Emre Yekedüz

Video

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

March 25th 2025, 7:05pm

By Spencer Feldman

Article

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

Navigating a Diagnosis of Diabetes and Chronic Lymphocytic Leukemia

March 25th 2025, 5:00pm

By Chester Freeman

Article

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.

Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer

March 25th 2025, 4:14pm

By Alex Biese

Article

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer

March 25th 2025, 3:34pm

By Spencer Feldman

Article

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.